Table 12.
AMR Outcome of Interest | Year/Metaphylaxis | DOF Comparison | OR | 95% CI | p-Value |
---|---|---|---|---|---|
Tetracycline | 2020/tulathromycin | 13DOF vs. 1DOF | 0.4 | 0.2, 0.7 | 0.001 |
36DOF vs. 1DOF | 1.1 | 0.4, 2.7 | 0.83 | ||
36DOF vs. 13DOF | 2.9 | 1, 8.2 | 0.052 | ||
2021/tulathromycin * | 13DOF vs. 1DOF ** | 0.3 | 0, 1.7 | 0.25 | |
36DOF vs. 1DOF ** | 0.9 | 0, 5.8 | 0.91 | ||
36DOF vs. 13DOF | · | · | · | ||
2021/oxytetracycline | 13DOF vs. 1DOF | 5.1 | 2.8, 9.3 | ≤0.001 | |
36DOF vs. 1DOF | 6.0 | 2.9, 12.6 | ≤0.001 | ||
36DOF vs. 13DOF | 1.2 | 0.7, 1.9 | 0.50 | ||
Spectinomycin | 2020/tulathromycin | 13DOF vs. 1DOF | 0.41 | 0.2, 0.7 | 0.001 |
36DOF vs. 1DOF | 1.02 | 0.4, 2.6 | 0.97 | ||
36DOF vs. 13DOF | 2.5 | 0.9, 6.9 | 0.084 | ||
2021/tulathromycin * | 13DOF vs. 1DOF ** | 0.1 | 0, 0.8 | 0.06 | |
36DOF vs. 1DOF ** | 0.5 | 0, 2.8 | 0.54 | ||
36DOF vs. 13DOF | · | · | · | ||
2021/oxytetracycline | 13DOF vs. 1DOF | 4.3 | 2.5, 7.5 | ≤0.001 | |
36DOF vs. 1DOF | 4.3 | 2.2, 8.3 | ≤0.001 | ||
36DOF vs. 13DOF | 1.0 | 0.6, 1.6 | 0.97 |
* Exact logistic regression equation performed. · odds ratio (OR) was not estimable. ** Indicates a median unbiased estimate.